156 related articles for article (PubMed ID: 3919531)
1. Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone.
Groop L; Harno K; Nikkilä EA; Pelkonen R; Tolppanen EM
Acta Med Scand; 1985; 217(1):33-9. PubMed ID: 3919531
[TBL] [Abstract][Full Text] [Related]
2. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients.
Kyllästinen M; Groop L
Ann Clin Res; 1985; 17(3):100-4. PubMed ID: 3931537
[TBL] [Abstract][Full Text] [Related]
3. The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes.
Groop L; Harno K; Tolppanen EM
Acta Endocrinol (Copenh); 1984 May; 106(1):97-101. PubMed ID: 6428120
[TBL] [Abstract][Full Text] [Related]
4. Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation.
Falko JM; Osei K
Am J Med; 1985 Sep; 79(3B):92-101. PubMed ID: 3931467
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
[TBL] [Abstract][Full Text] [Related]
6. Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
Osei K; O'Dorisio TM; Falko JM
Am J Med; 1984 Dec; 77(6):1002-9. PubMed ID: 6439036
[TBL] [Abstract][Full Text] [Related]
7. More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity.
Kabadi UM; McCoy S; Birkenholz M; Kabadi M
Diabet Med; 1995 Oct; 12(10):880-4. PubMed ID: 8846678
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
DeFronzo RA; Goodman AM
N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined insulin-sulfonylurea therapy in type II patients.
Lewitt MS; Yu VK; Rennie GC; Carter JN; Marel GM; Yue DK; Hooper MJ
Diabetes Care; 1989 Jun; 12(6):379-83. PubMed ID: 2499443
[TBL] [Abstract][Full Text] [Related]
10. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
Mauerhoff T; Ketelslegers JM; Lambert AE
Diabete Metab; 1986 Feb; 12(1):34-8. PubMed ID: 3084315
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.
Groop L; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
Diabetes Care; 1987; 10(6):671-8. PubMed ID: 3123184
[TBL] [Abstract][Full Text] [Related]
12. Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents.
Stenman S; Groop PH; Saloranta C; Tötterman KJ; Fyhrqvist F; Groop L
Diabetologia; 1988 Apr; 31(4):206-13. PubMed ID: 3133266
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
[TBL] [Abstract][Full Text] [Related]
14. [Combined treatment of type-2 diabetics with insulin and glibenclamide after secondary drug failure. Double-blind, insulin-placebo-controlled crossover study].
Rosak C; Schwarz O; Althoff PH; Schöffling K; Schmidt FH
Dtsch Med Wochenschr; 1985 Dec; 110(51-52):1975-80. PubMed ID: 3935405
[TBL] [Abstract][Full Text] [Related]
15. Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure.
Karlander SG; Gutniak MK; Efendic S
Diabetes Care; 1991 Nov; 14(11):963-7. PubMed ID: 1797509
[TBL] [Abstract][Full Text] [Related]
16. Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone.
Lardinois CK; Liu GC; Reaven GM
Arch Intern Med; 1985 Jun; 145(6):1028-32. PubMed ID: 3923961
[TBL] [Abstract][Full Text] [Related]
17. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy.
Lins PE; Lundblad S; Persson-Trotzig E; Adamson U
Acta Med Scand; 1988; 223(2):171-9. PubMed ID: 3126626
[TBL] [Abstract][Full Text] [Related]
18. Insulin and sulphonylurea in the therapy of type 2 diabetes.
Sotaniemi EA; Vierimaa E; Huupponen R; Karvonen I; Vuoti MJ; Rytömaa K
Diabetes Res Clin Pract; 1990 Mar; 8(3):243-51. PubMed ID: 2111239
[TBL] [Abstract][Full Text] [Related]
19. Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial.
Casner PR
Clin Pharmacol Ther; 1988 Nov; 44(5):594-603. PubMed ID: 3141099
[TBL] [Abstract][Full Text] [Related]
20. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Pugh JA; Wagner ML; Sawyer J; Ramirez G; Tuley M; Friedberg SJ
Diabetes Care; 1992 Aug; 15(8):953-9. PubMed ID: 1387073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
